Weill Medical College of Cornell University
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).
Breast Cancer
Radiation therapy - 3 weeks
Radiation therapy - 2 weeks
PHASE3
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 400 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental) |
Actual Study Start Date : | 2019-11-21 |
Estimated Primary Completion Date : | 2027-02-28 |
Estimated Study Completion Date : | 2030-02-28 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 19 Years to 90 Years |
Sexes Eligible for Study: | FEMALE |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
New York Presbyterian Hospital at Lower Manhattan Cancer Center
New York, New York, United States, 10007
RECRUITING
Brooklyn Methodist Hospital - NewYork Presbyterian
New York, New York, United States, 11215
RECRUITING
New York Presbyterian Hospital - Queens
New York, New York, United States, 11355